Business Growth
We help healthcare, pharma, and biotech companies simplify complexity with strategic guidance and actionable insights.
The challenge
Risk often hides between disciplines
Healthcare and life sciences diligence rarely fits within one discipline. Scientific, clinical, commercial, regulatory, operational, and investment decisions are interconnected. The challenge is not only collecting information, but understanding where assumptions and execution risk intersect.
Scientific complexity
Clinical translation, modality risk, technical differentiation, and biological uncertainty.
Commercial uncertainty
Adoption barriers, reimbursement, stakeholder incentives, and market timing.
Operation dependency
Manufacturing readiness, quality systems, vendors, and execution capabilities.
Fragmented information
Data rooms, narratives, assumptions, and operating realities often fail to align.
OUR APPROACH
Step 1: Diagnose
Start with a broad directional scan across the full diligence surface to identify opportunities, potential risks and the areas requiring deeper investigation.
Step 2: Assess
Conduct an in-depth review of operational, financial, commercial and technical aspects to understand their overall business impact.
Step 3: Verify
Validate findings through documentation, stakeholder interviews and third-party verification to ensure accuracy and consistency.
Step 4: Report
Present a comprehensive report with key findings, recommendations and strategic insights that support informed decision-making.
Adaptive diligence model
Diligence depth should match the decision being made
We begin with a light diagnostic to identify what matters most, then deepen selectively across the dimensions of highest uncertainty. The result is a more efficient diligence process that avoids overworking low-risk areas while giving critical risks the attention they require.
Diagnose
Light scan to identify which dimensions require deeper focus.
Isolate
Prioritise areas where risk, gaps, or uncertainty concentrate.
Deepen
Loop in specialist expertise to pressure-test specific domains.
Integrate
Convert findings into a decision-ready perspective.
Domains we assess
A cross-functional view of diligence
We evaluate the domains that drive value and risk in healthcare and life sciences, then adjust depth by dimension rather than forcing every engagement into the same format.
Scientific & Clinical
Scientific rationale, evidence quality, modality risk, clinical relevance, and translational feasibility.
Commercial & Market
Market attractiveness, adoption dynamics, reimbursement, buyer incentives, and competitive positioning.
Regulatory & Operational
Regulatory pathways, manufacturing readiness, CMC, vendor dependencies, and execution risk.
Strategic & Investment
Strategic fit, risk mapping, partnership relevance, exit pathways, and investment implications.
Who we support
Supporting decisions across healthcare and life sciences
Different groups face different forms of uncertainty. We help them evaluate opportunities clearly, identify gaps earlier, and prepare for higher-stakes decisions.
1
Emerging Companies
Typical Focus
Venture readiness and strategic preparation
- Evaluate investor readiness through an investor lens.
- Identify scientific, commercial, operational, and narrative gaps.
- Improve fundraising preparedness.
Helping companies prepare for institutional evaluation.
2
Investors & Capital Allocators
Typical Focus
Investment evaluation and risk assessment.
- Assess scientific and commercial viability.
- Evaluate execution and scalability risks.
- Identify hidden diligence gaps.
- Support investment committee decision-making.
Helping investors make higher-conviction decisions.
3
Accelerators & Venture Programs
Typical Focus
Cohort assessment and portfolio support
- Evaluate incoming startups and cohort quality.
- Identify readiness gaps across portfolio companies.
- Support commercialisation and strategic preparation
Helping accelerators improve portfolio quality and readiness.
4
Universities
& TTOs
Typical Focus
Commercial and translational assessment
- Evaluate translational and commercial potential.
- Assess strategic fit and market relevance.
- Identify venture creation and industry engagement pathways
Helping institutions assess how science can translate.
5
Investment Banks & Capital
Typical Focus
Preparation for large raises and transactions
- Prepare companies for institutional investor scrutiny.
- Support diligence readiness and strategic positioning.
- Complement banking and capital-raising processes
Helping strengthen company readiness ahead of larger
What we deliver
Outputs designed for decision-making
Scientific & technical reviews
Commercial assessment reports
Regulatory & operational reviews
Investment and risk memos
Market and competitive landscapes
Management and data room assessments
The Solution
Structured growth support across critical execution decisions.
We help organisations navigate the strategic and operational decisions that shape commercialisation, expansion, manufacturing, market entry, and long-term execution.
Selected engagements
Evidence of applied diligence
Where to play
Which opportunities, products, indications, modalities, customers, and markets should be prioritised first.
How to win
How products realistically achieve adoption through commercialisation, reimbursement, provider alignment, differentiation, and market positioning.
How to execute
How organisations structure manufacturing, supply chains, operating models, and execution pathways to scale sustainably.
How we help
The decisions that shape growth.
Growth in healthcare and life sciences is shaped by a series of strategic and operational decisions across products, manufacturing, commercialisation, operating models, and market expansion.
Which Products Move Forward?
Portfolio prioritisation, indication focus, resource concentration, and deciding which products or opportunities deserve deeper investment and execution focus
How Should Products Be Developed?
Clinical, manufacturing, regulatory, and commercial sequencing decisions that shape how products realistically move toward adoption.
What Should Be Built vs Outsourced?
Build versus outsource decisions across manufacturing, operations, supply chain, and execution capabilities.
Which Markets Should Be Prioritised?
Geographic sequencing, healthcare system alignment, reimbursement realities, and expansion readiness across different regions.
How Do Products Achieve Adoption?
Commercialisation, provider alignment, reimbursement strategy, market access, and go-to-market execution planning.
Our process
We take a structured and adaptive approach to growth execution.
Depending on the company, stage, product, modality, and geography involved, we selectively bring in the right commercial, operational, manufacturing, regulatory, and strategic expertise where deeper execution support is required.
Clarify
Understand priorities, growth constraints, operating realities, and strategic objectives.
Prioritise
Identify where focus, resources, and execution efforts should concentrate.
Structure
Align commercialisation, manufacturing, operating models, and market expansion pathways.
Execute
Support focused execution across scaling, commercialisation, market entry, and operational delivery.
Who we support
Built for companies across different stages of growth.
Our model adapts based on company stage and operating model.
1
Early-Stage Companies
Typical Focus
Scaling from validation toward commercial execution
- Clarify which product, indication, or market should be prioritised
- Identify the capabilities needed before scaling
- Prepare for commercial, operational, and market readiness
2
Growth-Stage & Mid-Cap Companies
Typical Focus
Scaling operations, commercialisation, and market expansion
- Assess whether the current operating model can support the next stage
- Support market expansion, manufacturing, supply, and go-to-market decisions
- Clarify what to build, outsource, or develop through external partners
3
Large Companies & Strategics
Typical Focus
Coordinating growth across larger operational and commercial systems
- Evaluate expansion opportunities and new market entry options
- Support capability, operating model, and commercial execution decisions
- Assess long-term strategic growth pathways across healthcare and life sciences markets
Why Nuvantta
Built for healthcare and life sciences growth execution.
Matched execution expertise
Engagement teams are aligned to the specific product, modality, operational challenge, and healthcare market involved.
Operator perspective
Commercial, manufacturing, operational, and execution realities are evaluated alongside strategic priorities.
Independent thinking
Structured and objective support designed to identify gaps, execution risks, and operational pressure points early.
Bench-to-market fluency
Ability to connect scientific innovation with commercialisation, manufacturing, market access, and operational execution.
Selected engagements
Evidence of applied diligence
Surgical Robotics Diligence
Assessed clinical, commercial, operational, and investment viability for a compact image-guided robotics platform.
Cellular Therapy Partnership
Evaluated strategic fit, operating feasibility, and commercial opportunity between a cell therapy company.
Pre-clinical RNA Investor Readiness
Reviewed scientific positioning, investor materials, strategic gaps, and fundraising narrative alignment.